F m Investments LLC Has $1.38 Million Stock Position in Soleno Therapeutics, Inc. $SLNO

F m Investments LLC reduced its holdings in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 46.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,871 shares of the company’s stock after selling 25,859 shares during the quarter. F m Investments LLC’s holdings in Soleno Therapeutics were worth $1,383,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Raymond James Financial Inc. acquired a new position in shares of Soleno Therapeutics during the second quarter valued at about $25,000. Danske Bank A S acquired a new position in shares of Soleno Therapeutics during the third quarter valued at about $27,000. Aster Capital Management DIFC Ltd purchased a new position in Soleno Therapeutics during the third quarter worth about $37,000. Quarry LP purchased a new position in Soleno Therapeutics during the third quarter worth about $47,000. Finally, Osaic Holdings Inc. boosted its holdings in Soleno Therapeutics by 97.7% during the second quarter. Osaic Holdings Inc. now owns 856 shares of the company’s stock worth $72,000 after purchasing an additional 423 shares during the last quarter. 97.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on SLNO shares. Cantor Fitzgerald cut shares of Soleno Therapeutics from an “overweight” rating to a “hold” rating and cut their price target for the stock from $123.00 to $53.00 in a report on Monday, April 6th. TD Cowen cut shares of Soleno Therapeutics from a “buy” rating to a “hold” rating and cut their price target for the stock from $85.00 to $53.00 in a report on Tuesday, April 7th. Wall Street Zen cut shares of Soleno Therapeutics from a “buy” rating to a “hold” rating in a report on Sunday, March 22nd. Wolfe Research cut shares of Soleno Therapeutics from an “outperform” rating to a “hold” rating in a report on Tuesday, April 7th. Finally, Oppenheimer cut their price target on shares of Soleno Therapeutics from $110.00 to $80.00 and set an “outperform” rating on the stock in a report on Wednesday, March 18th. Three investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Soleno Therapeutics presently has an average rating of “Hold” and an average target price of $76.67.

Soleno Therapeutics Price Performance

Soleno Therapeutics stock opened at $52.95 on Monday. The stock has a market cap of $2.76 billion, a PE ratio of 230.23 and a beta of -2.22. The company has a debt-to-equity ratio of 0.10, a quick ratio of 5.32 and a current ratio of 5.62. Soleno Therapeutics, Inc. has a fifty-two week low of $29.43 and a fifty-two week high of $90.32. The firm’s 50-day simple moving average is $43.27 and its 200 day simple moving average is $46.35.

Soleno Therapeutics (NASDAQ:SLNO) last announced its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.64 by $0.16. The business had revenue of $91.73 million for the quarter, compared to analyst estimates of $88.55 million. Soleno Therapeutics had a net margin of 33.70% and a return on equity of 22.85%. Research analysts predict that Soleno Therapeutics, Inc. will post 3.67 EPS for the current fiscal year.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.